Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
November 06 2017 - 8:30AM
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage
biopharmaceutical company developing novel antibiotics to treat
life-threatening multidrug-resistant (MDR) infections, today
announced that company management will present at the following
upcoming investor conferences:
- Stifel 2017 Healthcare Conference on Tuesday, November 14, 2017
at 8:00 a.m. Eastern Time at the Lotte New York Palace Hotel in New
York City
- PiperJaffray 29th Annual Healthcare Conference on Wednesday,
November 29, 2017 at 9:30 a.m. Eastern Time at the Lotte New York
Palace Hotel in New York City
Live audio webcasts of the presentations will be
available on the company’s website at
http://ir.tphase.com/events.cfm. Archived presentations will be
available for 30 days.
About Tetraphase Pharmaceuticals,
Inc.Tetraphase is a clinical-stage biopharmaceutical
company using its proprietary chemistry technology to create novel
antibiotics for serious and life-threatening bacterial infections,
including those caused by many of the multidrug-resistant (MDR)
bacteria highlighted as urgent public health threats by the CDC.
Tetraphase has created more than 3,000 novel tetracycline analogs
using its proprietary technology platform. Tetraphase's pipeline
includes three antibiotic clinical candidates: eravacycline, which
is in phase 3 clinical trials, and TP-271 and TP-6076, which are in
phase 1 clinical trials. Please visit www.tphase.com for more
company information.
Investor Contacts:
Tetraphase Pharmaceuticals
Teri Dahlman
617-600-7040
tdahlman@tphase.com
Argot PartnersMaeve
Conneighton206-899-4940maeve@argotpartners.com
Media Contact:
Sam Brown Inc.Mike Beyer312-961-2502mikebeyer@sambrown.com
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From Apr 2024 to May 2024
Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Historical Stock Chart
From May 2023 to May 2024